Evidence map›Paper›PMID 40595134›Full record

ArticleScientific reports2025

Design, synthesis, and anti-urease evaluations of new sulfonamide-1,2,3-triazole-acetamide derivatives.

Shohreh Bakhshi Varzaneh, Amir Shervin Shokouhi Asl, Mohammad Hosein Sayahi, Amir Mohammad Taherkhani, Meysam Talebi, Navid Dastyafteh, Sajedeh Safapoor, Mehdi Emadi, Majid Alikhani, Rozita Yazzaf and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shohreh Bakhshi Varzaneh *Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Amir Shervin Shokouhi Asl *Student Research Committee, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
Mohammad Hosein SayahiDepartment of Chemistry, Payame Noor University, Tehran, Iran.
Amir Mohammad TaherkhaniEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Meysam TalebiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Navid DastyaftehEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Sajedeh SafapoorEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mehdi EmadiElectrical and Computer Engineering Department, Babol Noshirvani University of Technology, Babol, Iran.
Majid AlikhaniDepartment of Internal Medicine, School of Medicine, Rheumatology Research Center Shariati Hospital, Tehran University of Medical Sciences,, Tehran, Iran.
Rozita YazzafSchool of Chemistry, College of Science, University of Tehran, Tehran, Iran.
Mohammad HalimiDepartment of Biology, Babol Branch, Islamic Azad University, Babol, Iran.
Massoud AmanlouDepartment of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Bagher LarijaniEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Maryam Mohammadi-KhanaposhtaniCellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. maryammoha@gmail.com.
Mohammad MahdaviEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. momahdavi@tums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study demonstrated the design and synthesis of sulfonamide-1,2,3-triazole-acetamide derivatives 11a-o and screening against urease in vitro and in silico. These compounds were designed based on reported potent urease inhibitors and optimized structurally based on substituents on acetamide moiety. In vitro studies showed that all the new compounds 11a-o (IC

Indexed as

AcetamidesDrug DesignEnzyme InhibitorsSulfonamidesTriazolesUreaseAnimalsHumansMolecular Docking SimulationStructure-Activity RelationshipacetamideAcetamidesEnzyme InhibitorsSulfonamidesTriazolesUrease1,2,3-Triazole-acetamideSulfonamideUrease inhibitors

Identifiers

PMID40595134
PMCPMC12215913

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.